The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Clinical characteristics & outcomes by age in the inMIND study of tafa+len+R in R/R FL
In this video, Christina Poh, MD, City of Hope, Duarte, CA, discusses the results of the inMIND trial (NCT04680052), which evaluated the efficacy and safety of adding tafasitamab (tafa) to lenalidomide (len) and rituximab (R) for relapsed/refractory (R/R) follicular lymphoma (FL), with a focus on the findings of an analysis assessing clinical characteristics and outcomes by age. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
